TECHNESCAN HDP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNESCAN HDP (TECHNESCAN HDP).
Technetium Tc-99m oxidronate (HDP) is a bone-seeking radiopharmaceutical that localizes to areas of osteoblastic activity. It binds to hydroxyapatite crystals in bone via chemisorption, allowing scintigraphic imaging of skeletal lesions.
| Metabolism | Tc-99m HDP is not metabolized; it is eliminated by renal excretion as unchanged drug with a biological half-life of 2-3 hours. |
| Excretion | Renal: >95% excreted unchanged in urine within 24 hours. Biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours for the diphosphonate component, with clinical imaging typically performed 2-4 hours post-injection. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Apparent Vd is 0.3-0.4 L/kg, distributed predominantly in extracellular fluid and bone. |
| Bioavailability | Not applicable; administered intravenously. |
| Onset of Action | Intravenous: Uptake into bone begins immediately; optimal imaging time is 2-4 hours post-injection. |
| Duration of Action | Skeletal uptake persists for several hours, allowing imaging within 2-4 hours; residual activity in soft tissues clears within 24 hours. |
For bone scintigraphy: 740 MBq (20 mCi) intravenous injection.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required; use with caution in severe renal impairment (GFR <30 mL/min). |
| Liver impairment | No dose adjustment necessary. |
| Pediatric use | Weight-based: 9.3 MBq/kg (0.25 mCi/kg) intravenous, minimum 37 MBq (1 mCi). |
| Geriatric use | No specific adjustment; follow adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNESCAN HDP (TECHNESCAN HDP).
| Breastfeeding | Breastfeeding should be discontinued for at least 24 hours after administration due to radioactive excretion into breast milk. M/P ratio not available. |
| Teratogenic Risk | Technetium Tc-99m oxidronate (HDP) is a radiopharmaceutical. In pregnancy, radiation exposure poses potential fetal risks, especially during organogenesis (first trimester) where risk of malformations and developmental delay is highest. Second and third trimester exposure is associated with increased risk of childhood cancer. Therefore, use is contraindicated unless benefit clearly outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to technetium Tc-99m oxidronate or any component of the formulation"]
| Precautions | ["Risk of hypersensitivity reactions including anaphylaxis","Use with caution in patients with renal impairment (may reduce clearance and increase radiation exposure)","Hydration and frequent voiding recommended to minimize bladder radiation dose"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal thyroid function if administered during pregnancy; ensure adequate hydration to promote voiding and reduce radiation dose. Fetal monitoring includes assessment of radiation exposure dose. |
| Fertility Effects | No known direct effects on fertility; however, gonadal radiation exposure may theoretically reduce fertility at high repeated doses. |